Solid reporting on whatmight be the most ambitious BCI approach yet. The ultrasound plus protein reporters combo is basically trying to sidestep the invasiveness problem that's kept BCIs in medical device territory. What's interesting is how this parallels the optogenetics revolution from a decade ago, where genetic encoding made neural activity visible. I've seen similar patterns in brain imaging research where penetration depth always traded off with resolution until someone figures out a molecular hack. The gene therapy delivery scalability issue is real tho.
I hope Ashlee gets an equity stake or finders fee for making the intro. On a more serious note, I wonder if there is a role to play for AlphaFold in designing new proteins that push this approach forward.
Fascinating piece—thanks for covering this! Have you seen Circulatronics out of MIT? https://news.mit.edu/2025/new-therapeutic-brain-implants-defy-surgery-need-1105
no. will check out!
Awesome scoop! Would love more interviews about the frontiers of gene therapy, targeting, editing, lowering cost, etc.
done!
Solid reporting on whatmight be the most ambitious BCI approach yet. The ultrasound plus protein reporters combo is basically trying to sidestep the invasiveness problem that's kept BCIs in medical device territory. What's interesting is how this parallels the optogenetics revolution from a decade ago, where genetic encoding made neural activity visible. I've seen similar patterns in brain imaging research where penetration depth always traded off with resolution until someone figures out a molecular hack. The gene therapy delivery scalability issue is real tho.
The logo looks like the old Atari logo.
it's pong for your mind
Ha! Brilliant.
I hope Ashlee gets an equity stake or finders fee for making the intro. On a more serious note, I wonder if there is a role to play for AlphaFold in designing new proteins that push this approach forward.
Right?